Fig. 1From: Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary diseasePatient flow chart of study profile. 1nivolumab or pembrolizumab. Abbreviations: CIP, checkpoint inhibitors related pneumonitis; COPD, chronic obstructive pulmonary diseaseBack to article page